Literature DB >> 28786831

Intestinal and Limb Ischemic Preconditioning Provides a Combined Protective Effect in the Late Phase, But not in the Early Phase, Against Intestinal Injury Induced by Intestinal Ischemia-Reperfusion in Rats.

Bo Yang1, Ye Chen2, Yan-Hong Long1, Xin Fan1, Ke-Xuan Liu3, Xiao-Bin Wang1, Jun Zhou1.   

Abstract

Intestinal ischemia/reperfusion (I/R) injury is associated with high morbidity and mortality. This study aimed to compare the protective efficacy of intestinal ischemic preconditioning (IIPC) and limb ischemic preconditioning (LIPC) against intestinal I/R injury and investigate their combined protective effect and the underlying mechanism. Male Sprague-Dawley rats were pretreated with IIPC, LIPC, or IIPC plus LIPC (combined), and intestinal I/R or sham operation was performed. The animals were sacrificed at 2 and 24 h after reperfusion and then blood and tissue samples were harvested for further analyses. In additional groups of animals, a 7-day survival study was conducted. The results showed that ischemic preconditioning (IPC) improved the survival rate and attenuated intestinal edema, injury, and apoptosis. IPC decreased the levels of tumor necrosis factor-α, interleukin -6, malondialdehyde and myeloperoxidase, and increased the activity of superoxide dismutase in serum and intestine after the I/R event. IPC downregulated the expression of Toll-like receptor-4 (TLR4) and nuclear factor-kappa B (NF-κB). The effect of combined pretreatment was better than that of single pretreatment in the late phase (24 h), but not in the early phase (2 h). The study demonstrated that IPC could significantly attenuate intestinal injury induced by intestinal I/R via inhibiting inflammation, oxidative stress, and apoptosis. IIPC and LIPC conferred no synergy in protecting I/R-induced intestinal injury in the early phase, but combined preconditioning had clearly stronger protection in the late phase, which was associated with the inhibition of the activated TLR4/NF-κB signaling pathway. It suggested that LIPC or combined preconditioning could potentially be applied in the clinical settings of surgical patient care.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28786831     DOI: 10.1097/SHK.0000000000000956

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  6 in total

1.  Amelioration of Coagulation Disorders and Inflammation by Hydrogen-Rich Solution Reduces Intestinal Ischemia/Reperfusion Injury in Rats through NF-κB/NLRP3 Pathway.

Authors:  Ling Yang; Yan Guo; Xin Fan; Ye Chen; Bo Yang; Ke-Xuan Liu; Jun Zhou
Journal:  Mediators Inflamm       Date:  2020-06-10       Impact factor: 4.711

2.  Irisin Contributes to the Hepatoprotection of Dexmedetomidine during Intestinal Ischemia/Reperfusion.

Authors:  Xin Fan; Juan Du; Mao-Hua Wang; Jia-Man Li; Bo Yang; Ye Chen; Jun-Chao Dai; Chunxiang Zhang; Jun Zhou
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

3.  Acute remote ischemic preconditioning alleviates free radical injury and inflammatory response in cerebral ischemia/reperfusion rats.

Authors:  Xian-Liang Meng; Dong-Lin Zhang; Shi-Hua Sui
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

4.  Limb Ischemic Postconditioning Alleviates Postcardiac Arrest Syndrome through the Inhibition of Mitochondrial Permeability Transition Pore Opening in a Porcine Model.

Authors:  Zhengquan Wang; Lifeng Wu; Jiefeng Xu; Jindan Gao; Sen Ye; Zilong Li; Yuanzhuo Chen; Xiangyu Zhang
Journal:  Biomed Res Int       Date:  2020-04-15       Impact factor: 3.411

5.  Irisin Protects Against Hind Limb Ischemia Reperfusion Injury.

Authors:  Ayşegül Küçük; Ali Doğan Dursun; Yücel Polat; Aydan Kılıçarslan; Nuran Süngü; Hakan Kartal; Mustafa Arslan
Journal:  Drug Des Devel Ther       Date:  2021-02-04       Impact factor: 4.162

6.  Faster Hypothermia Induced by Esophageal Cooling Improves Early Markers of Cardiac and Neurological Injury After Cardiac Arrest in Swine.

Authors:  Jiefeng Xu; Xiaohong Jin; Qijiang Chen; Chunshuang Wu; Zilong Li; Guangju Zhou; Yongan Xu; Anyu Qian; Yulin Li; Mao Zhang
Journal:  J Am Heart Assoc       Date:  2018-11-06       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.